Dual antiplatelet therapy, composed of aspirin plus a P 2 Y 12‐receptor antagonist, is the
cornerstone of treatment for patients with acute coronary syndrome (ACS). A number of US …

Inactivation of platelet cyclooxygenase (COX)-1 by low-dose aspirin leads to long-lasting
suppression of thromboxane (TX) A2 production and TXA2-mediated platelet activation and …

Background The relative merits of ticagrelor as compared with prasugrel in patients with
acute coronary syndromes for whom invasive evaluation is planned are uncertain. Methods …

Background The appropriate dose of aspirin to lower the risk of death, myocardial infarction,
and stroke and to minimize major bleeding in patients with established atherosclerotic …

Importance Determining the right dosage of aspirin for the secondary prevention treatment of
atherosclerotic cardiovascular disease (ASCVD) remains an unanswered and critical …

Aspirin represents the sine qua non for antiplatelet pharmacotherapy in patients with
cardiovascular diseases because of its well-established role in secondary prevention and its …

Objectives The 30‐day clinical outcomes with prasugrel or ticagrelor were compared using a
US payer database in patients with acute coronary syndrome (ACS) undergoing …

Over the past decade, the dramatic growth in the number of new prescriptions and over-the-
counter drugs has greatly improved the therapeutic armamentarium but at the expense of an …

Coronary artery disease (CAD) is the underlying cause of death in one out of seven deaths
in the USA. Aspirin therapy has been proven to decrease mortality and major adverse …

Introduction: Potent platelet inhibition reduces the risk of thrombotic complications including
myocardial infarction and death in patients with acute coronary syndrome (ACS). Targeting …